{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:44:03Z","timestamp":1792125843443,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,1,17]],"date-time":"2014-01-17T00:00:00Z","timestamp":1389916800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s00280-014-2384-1","type":"journal-article","created":{"date-parts":[[2014,1,16]],"date-time":"2014-01-16T15:38:57Z","timestamp":1389886737000},"page":"495-501","source":"Crossref","is-referenced-by-count":47,"title":["Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers"],"prefix":"10.1007","volume":"73","author":[{"given":"Jennifer J.","family":"Wheler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Janku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald S.","family":"Falchook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffiny L.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aung","family":"Naing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostalia M.","family":"Tsimberidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy L.","family":"Moulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina A.","family":"Piha-Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnique T.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,17]]},"reference":[{"key":"2384_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.med.57.121304.131306","volume":"57","author":"J Folkman","year":"2006","unstructured":"Folkman J (2006) Angiogenesis. Annu Rev Med 57:1\u201318. doi: 10.1146\/annurev.med.57.121304.131306","journal-title":"Annu Rev Med"},{"issue":"1","key":"2384_CR2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1096\/fasebj.13.1.9","volume":"13","author":"G Neufeld","year":"1999","unstructured":"Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13(1):9\u201322","journal-title":"FASEB J"},{"issue":"4","key":"2384_CR3","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","volume":"23","author":"KD Miller","year":"2005","unstructured":"Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23(4):792\u2013799. doi: 10.1200\/JCO.2005.05.098","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"2384_CR4","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.3816\/CCC.2004.s.010","volume":"4","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H (2004) Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer 4(Suppl 2):S62\u2013S68","journal-title":"Clin Colorectal Cancer"},{"issue":"15 Pt 2","key":"2384_CR5","doi-asserted-by":"crossref","first-page":"s4613","DOI":"10.1158\/1078-0432.CCR-07-0647","volume":"13","author":"A Sandler","year":"2007","unstructured":"Sandler A (2007) Bevacizumab in non small cell lung cancer. Clin Cancer Res 13(15 Pt 2):s4613\u2013s4616. doi: 10.1158\/1078-0432.CCR-07-0647","journal-title":"Clin Cancer Res"},{"issue":"28","key":"2384_CR6","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733\u20134740. doi: 10.1200\/JCO.2008.19.8721","journal-title":"J Clin Oncol"},{"issue":"9605","key":"2384_CR7","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"B Escudier","year":"2007","unstructured":"Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605):2103\u20132111. doi: 10.1016\/S0140-6736(07)61904-7","journal-title":"Lancet"},{"key":"2384_CR8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0065-230X(04)91004-4","volume":"91","author":"PA Marks","year":"2004","unstructured":"Marks PA, Richon VM, Miller T, Kelly WK (2004) Histone deacetylase inhibitors. Adv Cancer Res 91:137\u2013168. doi: 10.1016\/S0065-230X(04)91004-4","journal-title":"Adv Cancer Res"},{"issue":"3","key":"2384_CR9","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35106079","volume":"1","author":"P Marks","year":"2001","unstructured":"Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1(3):194\u2013202. doi: 10.1038\/35106079","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2384_CR10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1527-3458.2003.tb00249.x","volume":"9","author":"CU Johannessen","year":"2003","unstructured":"Johannessen CU, Johannessen SI (2003) Valproate: past, present, and future. CNS Drug Rev 9(2):199\u2013216","journal-title":"CNS Drug Rev"},{"issue":"3","key":"2384_CR11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.onc.1205108","volume":"21","author":"CF Deroanne","year":"2002","unstructured":"Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N, Blacher S, Verdin E, Foidart JM, Nusgens BV, Castronovo V (2002) Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21(3):427\u2013436. doi: 10.1038\/sj.onc.1205108","journal-title":"Oncogene"},{"issue":"4","key":"2384_CR12","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/86507","volume":"7","author":"MS Kim","year":"2001","unstructured":"Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, Moon EJ, Kim HS, Lee SK, Chung HY, Kim CW, Kim KW (2001) Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7(4):437\u2013443. doi: 10.1038\/86507","journal-title":"Nat Med"},{"issue":"18","key":"2384_CR13","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1158\/0008-5472.CAN-04-0540","volume":"64","author":"DZ Qian","year":"2004","unstructured":"Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L, Atadja P, Pili R (2004) The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787\/ZK222584. Cancer Res 64(18):6626\u20136634. doi: 10.1158\/0008-5472.CAN-04-0540","journal-title":"Cancer Res"},{"issue":"6","key":"2384_CR14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649\u2013655","journal-title":"Am J Clin Oncol"},{"key":"2384_CR15","unstructured":"Criteria Committee of the New York Heart Association (1994) Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th edn. Little Brown & Co, Boston"},{"issue":"19","key":"2384_CR16","doi-asserted-by":"crossref","first-page":"6296","DOI":"10.1158\/1078-0432.CCR-08-1247","volume":"14","author":"F Braiteh","year":"2008","unstructured":"Braiteh F, Soriano AO, Garcia-Manero G, Hong D, Johnson MM, Silva Lde P, Yang H, Alexander S, Wolff J, Kurzrock R (2008) Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res 14(19):6296\u20136301. doi: 10.1158\/1078-0432.CCR-08-1247","journal-title":"Clin Cancer Res"},{"issue":"39","key":"2384_CR17","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","volume":"276","author":"CJ Phiel","year":"2001","unstructured":"Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276(39):36734\u201336741. doi: 10.1074\/jbc.M101287200","journal-title":"J Biol Chem"},{"issue":"3","key":"2384_CR18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"2384_CR19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"2384_CR20","first-page":"163","volume":"50","author":"N Mantel","year":"1966","unstructured":"Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50(3):163\u2013170","journal-title":"Cancer Chemother Rep"},{"issue":"9","key":"2384_CR21","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMsa042220","volume":"352","author":"E Horstmann","year":"2005","unstructured":"Horstmann E, McCabe MS, Grochow L, Yamamoto S, Rubinstein L, Budd T, Shoemaker D, Emanuel EJ, Grady C (2005) Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352(9):895\u2013904. doi: 10.1056\/NEJMsa042220","journal-title":"N Engl J Med"},{"issue":"9","key":"2384_CR22","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","volume":"102","author":"ML Maitland","year":"2010","unstructured":"Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, Ivy SP, Leier CV, Lindenfeld J, Liu G, Remick SC, Steingart R, Tang WH (2010) Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 102(9):596\u2013604. doi: 10.1093\/jnci\/djq091","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2384_CR23","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","volume":"49","author":"X Zhu","year":"2007","unstructured":"Zhu X, Wu S, Dahut WL, Parikh CR (2007) Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49(2):186\u2013193. doi: 10.1053\/j.ajkd.2006.11.039","journal-title":"Am J Kidney Dis"},{"issue":"28","key":"2384_CR24","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1200\/JCO.2008.16.1612","volume":"26","author":"BP Schneider","year":"2008","unstructured":"Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26(28):4672\u20134678. doi: 10.1200\/JCO.2008.16.1612","journal-title":"J Clin Oncol"},{"issue":"6","key":"2384_CR25","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1200\/JCO.2009.25.4482","volume":"28","author":"SE Dahlberg","year":"2010","unstructured":"Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH (2010) Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 28(6):949\u2013954. doi: 10.1200\/JCO.2009.25.4482","journal-title":"J Clin Oncol"},{"issue":"2","key":"2384_CR26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/annonc\/mdn637","volume":"20","author":"M Scartozzi","year":"2009","unstructured":"Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, Cascinu S (2009) Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 20(2):227\u2013230. doi: 10.1093\/annonc\/mdn637","journal-title":"Ann Oncol"},{"issue":"2","key":"2384_CR27","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/annonc\/mdn729","volume":"20","author":"P Bono","year":"2009","unstructured":"Bono P, Elfving H, Utriainen T, Osterlund P, Saarto T, Alanko T, Joensuu H (2009) Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol 20(2):393\u2013394. doi: 10.1093\/annonc\/mdn729","journal-title":"Ann Oncol"},{"issue":"10","key":"2384_CR28","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1182\/blood-2006-03-009142","volume":"108","author":"G Garcia-Manero","year":"2006","unstructured":"Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O\u2019Brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP (2006) Phase 1\/2 study of the combination of 5-aza-2\u2032-deoxycytidine with valproic acid in patients with leukemia. Blood 108(10):3271\u20133279. doi: 10.1182\/blood-2006-03-009142","journal-title":"Blood"},{"issue":"7","key":"2384_CR29","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1182\/blood-2007-03-078576","volume":"110","author":"AO Soriano","year":"2007","unstructured":"Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM, Garcia-Manero G (2007) Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110(7):2302\u20132308. doi: 10.1182\/blood-2007-03-078576","journal-title":"Blood"},{"issue":"4","key":"2384_CR30","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2007-10-115873","volume":"112","author":"G Garcia-Manero","year":"2008","unstructured":"Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H, Newsome WM, Miller WH Jr, Rousseau C, Kalita A, Bonfils C, Dubay M, Patterson TA, Li Z, Besterman JM, Reid G, Laille E, Martell RE, Minden M (2008) Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 112(4):981\u2013989. doi: 10.1182\/blood-2007-10-115873","journal-title":"Blood"},{"issue":"3","key":"2384_CR31","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2007-06-098061","volume":"111","author":"G Garcia-Manero","year":"2008","unstructured":"Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM (2008) Phase 1 study of the histone deacetylase inhibitor vorinostat [suberoylanilide hydroxamic acid (SAHA)] in patients with advanced leukemias and myelodysplastic syndromes. Blood 111(3):1060\u20131066. doi: 10.1182\/blood-2007-06-098061","journal-title":"Blood"},{"issue":"17","key":"2384_CR32","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","volume":"23","author":"WK Kelly","year":"2005","unstructured":"Kelly WK, O\u2019Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23(17):3923\u20133931. doi: 10.1200\/JCO.2005.14.167","journal-title":"J Clin Oncol"},{"issue":"17","key":"2384_CR33","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1200\/JCO.2005.02.188","volume":"23","author":"QC Ryan","year":"2005","unstructured":"Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J, Figg WD, Hwang K, Chung EJ, Murgo A, Melillo G, Elsayed Y, Monga M, Kalnitskiy M, Zwiebel J, Sausville EA (2005) Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 23(17):3912\u20133922. doi: 10.1200\/JCO.2005.02.188","journal-title":"J Clin Oncol"},{"issue":"4","key":"2384_CR34","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1182\/blood-2005-09-008086","volume":"108","author":"B Sanchez-Gonzalez","year":"2006","unstructured":"Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, Hoshino K, Quintas-Cardama A, Richon VM, Garcia-Manero G (2006) Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood 108(4):1174\u20131182. doi: 10.1182\/blood-2005-09-008086","journal-title":"Blood"},{"issue":"1","key":"2384_CR35","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2141.2010.08211.x","volume":"150","author":"TM Kadia","year":"2010","unstructured":"Kadia TM, Yang H, Ferrajoli A, Maddipotti S, Schroeder C, Madden TL, Holleran JL, Egorin MJ, Ravandi F, Thomas DA, Newsome W, Sanchez-Gonzalez B, Zwiebel JA, Espinoza-Delgado I, Kantarjian HM, Garcia-Manero G (2010) A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol 150(1):72\u201382. doi: 10.1111\/j.1365-2141.2010.08211.x","journal-title":"Br J Haematol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2384-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2384-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2384-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T06:56:09Z","timestamp":1716447369000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2384-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,17]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["2384"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2384-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,17]]}}}